$A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide$

A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B...

Full description

Bibliographic Details
Main Authors:	Mamatha Siricilla, Lydia Irwin, Andres Ferber
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	Case Reports in Oncological Medicine
Online Access:	http://dx.doi.org/10.1155/2018/6137454

Similar Items

Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL): Early outcomes
by: Bhavin Visariya, et al.
Published: (2016-01-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Simultaneous myelodisplasia and multiple myeloma successfully treated with lenalidomide
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
by: Joan Manel Gasent Blesa, et al.
Published: (2012-04-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
by: Lili Cheng, et al.
Published: (2021-07-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)

30 Refractory cutaneous lupus: use of thalidomide or lenalidomide for refractory lupus skin disease
by: François Chasset
Published: (2021-04-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Lenalidomide: An Alternative Treatment for Refractory Behçet’s Disease and Relapsing Polychondritis
by: Sofia Gomes Brazao, et al.
Published: (2019-05-01)

Successful Control of Acute Myelofibrosis with Lenalidomide
by: G. Vassilopoulos, et al.
Published: (2010-01-01)

Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide
by: Kazuhito Suzuki, et al.
Published: (2020-03-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
by: Schmidt-Wolf, Ingo G. H., et al.
Published: (2011-01-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
by: Garcia-Recio M, et al.
Published: (2018-10-01)

Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report
by: Juliana Todaro, et al.

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
by: Catherine S. Y. Lecat, et al.
Published: (2021-07-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma
by: Kolonic Slobodanka, et al.
Published: (2010-05-01)

Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis Complicated by Massive Splenomegaly Treated with Lenalidomide Resulting in Resolution of Splenomegaly but Severe and Prolonged Pancytopenia
by: Gordon Taylor, et al.
Published: (2013-01-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
by: Lee YP, et al.
Published: (2021-05-01)

Refractory pemphigus vulgaris successfully treated with ofatumumab
by: Daniel M. Klufas, MD, et al.
Published: (2020-08-01)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
by: Tomoki Ito, et al.
Published: (2018-01-01)

Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide
by: Iuliana Vaxman, et al.
Published: (2020-01-01)

Lenalidomide-Associated ITP
by: Christina I. Herold, et al.
Published: (2011-01-01)

Thymic Carcinoma Presenting as Disseminated Intravascular Coagulation
by: Mamatha Siricilla, et al.
Published: (2014-01-01)

Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
by: Satoko Oka, et al.
Published: (2019-01-01)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
by: Peng‐Fei Zhang, et al.
Published: (2020-08-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

A rare case report of photosensitivity in non-hodgkin's lymphoma treated with lenalidomide
by: Rajesh K Soni, et al.
Published: (2020-01-01)

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01)

Cannot write session to /tmp/vufind_sessions/sess_o6mr490avivo0gl2uucbq22jke